Endo Pharmaceuticals Solutions (IDEV) Inactive 10-Q2007 Q3 Quarterly report

Filed: 9 Aug 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: abstaining, acceleration, advisory, Agent, Andrew, appointment, approach, broker, Cheryl, commensurate, comparison, composed, concentration, consecutive, David, deductible, detailed, discretion, disposition, distributor, DSU, executory, exemption, Ferrara, firm, forma, fourteen, Gale, Hanson, inherent, interval, LLP, mailed, Malcolm, maximum, McCluski, Morley, Morville, naltrexone, NEDBIDO, nonrefundable, outlier, permitted, plant, provisional, proxy, ratified, ratify, redemption, responder, seventeen, Sharrock, Spepharm, Stephen, subscription, threshold, trospiun, Trust, unfunded, unsecured, withheld, York

Removed: administration, assuming, conducting, exercisable, historically, Item, level, past, proceed, prospective, revert, shown, tolerated, underlying, volume, weighted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

IDEV similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 10.1

On April 30, 2007, Deferred Stock Units (DSUs) were granted to each non-employee member of the Board of Directors of Indevus Pharmaceuticals, Inc. (the “Company”) pursuant to the Company’s 2004 Equity Incentive Plan. Each director received 8,000 DSUs and each DSU represents the right to receive one share of the Company’s common stock. The DSUs vest over three years and the vested portion of the award is distributable after the earlier of the Director’s retirement from the Board or five years from the date of grant.